FGF23 and hypophosphatemia: Similarly to MAS, CSHS is characterized by the overproduction of FGF23, secreted by osteocytes in affected dysplastic bones, resulting in hypophosphatemia, bone pain, rickets, long bone deformity, impaired growth and mobility (1).